Please login to the form below
Corlaner
This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.
Amgen takes aim at cardio diseases with Arrowhead RNAi deal
Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.
Latest news
-
Amgen starts shipping Corlaner in US
Firm also reports healthy financial growth in the first quarter. . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic
-
FDA clears Amgen's Corlaner for heart failure
The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of
-
Amgen banking on three launches in 2015
year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Heart failure therapy embarks on a new era
Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
